Amber Therapeutics is developing the Picostim™ System, a fully implantable device that utilizes adaptive pudendal neuromodulation to treat mixed urinary incontinence by dynamically stimulating the pudendal nerve based on real-time physiological feedback. This therapy addresses the significant unmet need of over 40 million women in the U.S. suffering from this debilitating condition, with promising clinical results demonstrating improved quality of life.

Capstan Medical develops technology that merges surgical robotics with catheter-based systems for structural heart disease treatment. The company focuses on providing a less invasive approach for repairing and replacing heart valves compared to traditional open-heart surgery. This innovation aims to ensure precise implant placement while reducing patient recovery time and complication risks.

Endogenex is developing the ReCET™ System, which utilizes controlled, non-thermal pulsed electric fields delivered endoscopically to reset metabolic signaling in the duodenum. This approach aims to restore metabolic function and improve blood glucose control for patients with type 2 diabetes.

The startup offers a cloud-based research data management platform that automates workflows for biomedical research, enabling collaborative studies and machine learning applications. This platform enhances data scalability and analysis, facilitating multicenter clinical trials and accelerating the pace of scientific discoveries.

KelaHealth provides an AI-enabled API that delivers patient-specific predictive insights and recommended interventions at critical decision points in the surgical process. This technology enhances existing medical applications, improving patient throughput, care team productivity, and overall surgical outcomes by identifying individual patient risks and optimizing clinical operations.

MedCrypt provides a cybersecurity platform that includes SBOM and vulnerability management tools to help medical device manufacturers meet FDA compliance requirements. Their services ensure secure device management and ongoing monitoring, addressing the risks of data breaches and regulatory delays in the medical device industry.

Neocis offers the Yomi system, an FDA‑cleared robot‑assisted platform for dental implant surgery. The system combines pre‑operative planning with intra‑operative robotic guidance to improve placement accuracy, streamline workflow, and raise the standard of care in implantology.

Optellum develops AI-based decision support software that utilizes imaging biomarkers to enhance the early detection of lung cancer. This technology enables clinicians to identify at-risk patients and optimize their management strategies, improving patient outcomes in lung health care.

SURGE Therapeutics has developed a biodegradable hydrogel that delivers localized cancer immunotherapy during surgical tumor resection, targeting residual cancer cells to prevent post-surgical recurrence and metastasis. This approach addresses the issue of immune suppression caused by surgery, which contributes to over 40% of patients experiencing relapse within five years.

XII Medical develops minimally invasive neuromodulation therapies for obstructive sleep apnea, enhancing patient access to effective treatment options. Their technology aims to improve clinical outcomes by simplifying the therapeutic process and reducing the need for invasive procedures.